Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | NAMPT | P43490 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | ESRRG | P62508 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KDM5A | P29375 | 1/20 | 0.59 |
| ▸ | KDM5C | P41229 | 1/20 | 0.59 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568235 | 0.93 | RAB9A (1.00) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL17673049 | 0.92 | RAB9A (0.97) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL28919396 | 0.91 | RAB9A (0.78) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL2357555 | 0.90 | RAB9A (0.79) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL3818841 | 0.88 | RAB9A (0.83) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL751214 | 0.88 | HDAC2 (0.80) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| Hydrochloric Acid SCHEMBL28193721 | 0.86 | HDAC2 (0.77) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL13211715 | 0.84 | RAB9A (1.00) | RAB9AHDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL1568233 | 0.84 | RAB9A (0.82) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14547371 | 0.84 | HDAC2 (0.75) | RAB9AHDAC2HDAC8HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| JP-2002532414-A | — | — | 2002-10-02 | — | — | JP | claimed |
| EP-1140046-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035435-A9 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER LAMBERT CO (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20250042920-A1 | IMIDAZOTHIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4442692-A1 | IMIDAZOTHIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Ocean University of China (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | US | disclosed |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2006008192-A1 | N-[2-(4-PYRIDINYL)ETHYL]BENZAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2006-01-26 | — | — | WO | disclosed |
| US-6492363-B2 | FOR THERAPY OF CANCER AND OTHER PROLIFERATIVE DISEASES SUCH AS INFLAMMATION, PSORIASIS AND RESTENOSIS, AS WELL AS STROKE, HEART FAILURE, AND IMMUNODEFICIENCY DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| EP-1202726-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6310060-B1 | FOR USE AS ANTIPROLIFERATIVE AGENT FOR USE AGAINST CANCER, PSORIASIS, RESTENOSIS, AUTOIMMUNE DISEASE, OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2001-10-30 | — | — | US | disclosed |
| US-6251943-B1 | 2-(2-AMINO-3-METHOXYPHENYL)4-OXO-4H-(1)BENZOPYRAN A MEK INHIBITOR FOR THE TREATMENT OR PREVENTION OF SEPTIC SHOCK | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | RAB9A 3071/4885HDAC2 3888/4885HDAC8 3082/4885 |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | RAB9A 3126/4885HDAC2 2469/4885HDAC8 950/4885 |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | RAB9A 391/4885HDAC2 1227/4885HDAC8 2096/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | RAB9A 787/4885HDAC2 1860/4885HDAC8 2443/4885 |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | RAB9A 391/4885HDAC2 1227/4885HDAC8 2096/4885 |
| US-20250042920-A1 | IMIDAZOTHIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE2, WEE1, GCK | RAB9A 3797/4885HDAC2 803/4885HDAC8 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.